ERAS ▼ -8.1% - Erasca, Inc. $ERAS - Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat 17-NOV-2026 06:40 PM ET